Introduction {#S1}
============

Worldwide, the prevalence of atrial fibrillation (AF) is around 1--2% ([@B44]). Mutations in cardiac genes account for onset of 5--15% of AF cases ([@B11]; [@B44]). Mutations in *KCNA5* are associated with AF, although rare ([@B20]). *KCNA5* encodes the pore-forming α-subunit K~v~1.5 of the channel carrying the ultrarapid delayed rectifier K^+^ current (I~Kur~) ([@B19]; [@B49]). In the human heart, K~v~1.5 and the mRNA encoding K~v~1.5 are both highly expressed in the atria ([@B17]; [@B23]), whereas expression of K~v~1.5 is very low in both endocardial and epicardial ventricular tissue ([@B35]; [@B23]) and expression of mRNA encoding K~v~1.5 is also low ([@B29]; [@B23]). Accordingly, in their voltage clamp experiments on isolated human atrial and subepicardial ventricular myocytes, [@B2] could not observe an I~Kur~-like current in their ventricular myocytes, in contrast to their atrial myocytes. I~Kur~ activates rapidly upon depolarizations to membrane potentials positive to −50 mV and is responsible for the early repolarization in human atrial action potentials (APs) ([@B49]; [@B2]; [@B51]; [@B32]).

Both loss-of-function and gain-of-function mutations in *KCNA5* have been identified in patients with AF ([@B40]; [@B55], [@B54]; [@B6]; [@B25]; [@B46]). Loss-of-function mutations in *KCNA5* are supposed to increase susceptibility to AF by prolonging the AP duration (APD) of atrial myocytes, which may eventually result in early afterdepolarizations (EADs) ([@B55]; [@B25]). Indeed, *in vitro* electrophysiological studies where I~Kur~ was blocked, representing complete *KCNA5* loss-of-function mutations, resulted in prolonged APDs and presence of EADs ([@B40]). EADs as a consequence of prolonged APDs have also been observed in *in silico* studies on loss-of-function *KCNA5* mutations ([@B7]; [@B39]).

Gain-of-function mutations, on the other hand, are presumed to cause AF by shortening the effective refractory period (ERP) of the atrial AP, facilitating re-entry wavelets in the atria ([@B37]; [@B6]). This hypothesis is supported by *in silico* studies, which demonstrated that increased I~Kur~ density, representing gain-of-function mutations, resulted in a shortened APD and arrhythmogenesis in human atrial tissue ([@B7]; [@B39]).

Although the *in silico* studies are instrumental in determining the potential effect of both loss-of-function and gain-of-function mutations in *KCNA5*, detailed electrophysiological studies of the *KCNA5* mutations in human cardiomyocytes are limited. Human induced pluripotent stem cell cardiomyocytes (hiPSC-CMs) have become a highly suitable tool to study cardiac ion channelopathies and their electrophysiology ([@B56]; [@B26]; [@B48]). Over time, the technique of cardiomyocyte differentiation has advanced, facilitating the generation of distinct atrial- and ventricular-like hiPSC-CM populations ([@B56]; [@B14]; [@B13]). In the present study, we employed dynamic clamp to investigate the effects of loss-of-function and gain-of-function mutations in *KCNA5* in both atrial- and ventricular-like hiPSC-CMs.

Materials and Methods {#S2}
=====================

hiPSC-CM Differentiation {#S2.SS1}
------------------------

hiPSC-CMs were generated from the control LUMC0099iCTRL04 hiPSC line, which was derived from human fibroblasts extracted through skin biopsies from of a Caucasian woman. The LUMC0099iCTRL04 line is registered in the Human Pluripotent Stem Cell Registry ([@B45]), which contains all details pertaining to its generation and characterization ([@B28]). hiPSC clones showing stem cell morphology were characterized for pluripotency marker expression and differentiation potential to hiPSC-CMs in BPEL medium ([@B38]) containing activin-A, BMP4, and CHIR99021 ([@B12]). After 3 days, this medium was replaced by BPEL medium containing XAV939 (Tocris Biosciences) for ventricular differentiation ([@B38]; [@B12]). To differentiate hiPSC-CMs to atrial-like hiPSC-CMs, 1 μM all-trans retinoic acid (RA) was added ([@B14]). Twenty days after differentiation, hiPSC-CMs were dissociated with TrypLE Select (Life Technologies), and plated at a low density (≈7.5 × 10^4^ cells) on Matrigel coated coverslips in BPEL medium ([@B12]).

Patch-Clamp Measurements {#S2.SS2}
------------------------

### Data Acquisition {#S2.SS2.SSS1}

Electrophysiological recordings were performed 4--13 days post dissociation from spontaneously beating single hiPSC-CMs. RA-treated hiPSC-CMs displaying a short, pulse-like beating pattern and non-RA-treated hiPSC-CMs with a contraction-like beating pattern were selected for data acquisition. APs and I~Kur~ were recorded at 36--37°C with the perforated patch-clamp technique using an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA, United States). Data acquisition and analysis were performed with custom software. Signals were low-pass filtered with a cut-off frequency of 2 kHz and digitized at 40 and 5 kHz for AP and I~Kur~ recordings, respectively. Cell membrane capacitance (C~m~, in pF) was calculated by dividing the time constant of the decay of capacitive transient when hyperpolarized by 5 mV from −40 mV in voltage clamp by series resistance. C~m~ of atrial- and ventricular-like hiPSC-CMs was 16.4 ± 2.3 pF (mean ± SEM, *n* = 28), and 19.2 ± 2.5 pF (*n* = 27), respectively (*t*-test, N.S.). Patch pipettes with a resistance of ≈2.0 MΩ were pulled from borosilicate glass (Harvard Apparatus) and filled with solution containing (in mM): 125 [K]{.smallcaps}-gluconate, 20 KCl, 5 NaCl, 0.44 Amphotericin-B, 10 HEPES; pH set to 7.2 (KOH). Cells were superfused with modified Tyrode's solution containing (in mM): 140 NaCl, 5.4 KCl, 1.8 CaCl~2~, 1.0 MgCl~2~, 5.5 [D]{.smallcaps}-glucose, 5 HEPES; pH set to 7.4 (NaOH). All potentials were corrected for the estimated liquid junction potential of −15 mV ([@B4]).

### Action Potential Recordings {#S2.SS2.SSS2}

APs were elicited at 1 Hz by 3-ms, ≈1.2 × threshold current pulses through the patch pipette. The AP parameters analyzed were resting membrane potential (RMP, in mV), maximum upstroke velocity (dV/dt~max~, in V/s), AP amplitude (APA, in mV), AP duration at 20, 50, and 90% repolarization (APD~20~, APD~50~, and APD~90~, respectively, in ms), and AP plateau amplitude (APPlatA, in mV), derived from the membrane potential (V~m~) at 50 ms after the time of dV/dt~max~.

### Native I~Kur~ Recordings {#S2.SS2.SSS3}

Native I~Kur~ was activated by 200-ms voltage clamp steps from −50 to +50 mV. A 50-ms prepulse to 0 mV was applied to activate and inactivate remaining transient membrane currents. Series resistance was compensated by ≥ 80%. I~Kur~ was measured as the current sensitive to 50 μM 4-aminopyridine (4-AP) ([@B49]; [@B5]), and was normalized to C~m~ to calculate current density (in pA/pF).

### Dynamic Clamp {#S2.SS2.SSS4}

Although inward rectifier K^+^ current (I~K1~) is not necessarily low in hiPSC-CMs ([@B27]), hiPSC-CMs tend to lack I~K1~, which is responsible for stabilizing the RMP of atrial and ventricular myocytes, and thus show spontaneous activity ([@B15]; [@B26]; [@B48]). The RMP of our atrial- and ventricular-like hiPSC-CMs was stabilized and set at a regular hyperpolarized value using the dynamic clamp technique ([@B52]). A virtual Kir2.1-based I~K1~, with a standard peak current density of 2 pA/pF, was injected into the hiPSC-CMs and this I~K1~ was computed in real time, based on the acquired V~m~, following the approach of [@B36]. Accordingly, the mathematical equation for I~K1~ reads
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In this equation, in which the rectification properties of I~K1~ are implemented through a Boltzmann equation, I~K1~ is in pA/pF and V~m~ is in mV. E~K~ is the Nernst potential for potassium, which amounts to −86.9 mV in our experimental setting.

The effect of the injection of this virtual I~K1~ is illustrated in [Figure 1](#F1){ref-type="fig"}, which shows the APs of typical atrial-like and ventricular-like hiPSC-CMs in the absence and presence of this virtual I~K1~ (top panels) and the associated injected current (bottom panels), which consists of this I~K1~ and a short inward stimulus current. A virtual Kir2.1-based I~K1~, characteristic for human ventricular myocytes ([@B50]), was used in both atrial- and ventricular-like hiPSC-CMs because a more 'atrial-like' I~K1~ in hiPSC-CMs results in a substantial current during early repolarization due to its reduced rectification ([@B36]; [@B48]; [@B18]), and we wanted to prevent a prominent overlap and potential interference of I~K1~ and I~Kur~ during the course of an action potential.

![Typical action potentials (APs) of atrial- and ventricular-like hiPSC-CM with and without I~K1~ injection. **(A)** Superimposed APs (top panel) of an atrial-like hiPSC-CM in absence (black line) and presence (red line) of 100% virtual I~K1~ injected through dynamic clamp and associated injected current (bottom panel) consisting of stimulus current and 0% or 100% virtual I~K1~. **(B)** Superimposed APs and associated injected current of a ventricular-like hiPSC-CM. APs elicited at 1 Hz by a 3-ms stimulus of 100 pA. Note difference in time scale between panels **(A,B)**.](fcell-08-00536-g001){#F1}

The dynamic clamp technique was also used to provide our atrial- and ventricular-like hiPSC-CMs with a virtual wild-type or mutant I~Kur~, as illustrated in [Figure 2](#F2){ref-type="fig"}. Like I~K1~, I~Kur~ was computed in real time, based on the acquired value of V~m~. I~Kur~ was formulated as detailed in Section "I~Kur~ Equations" below. Virtual I~Kur~ was injected into atrial- and ventricular-like hiPSC-CMs with a fully activated conductance of 12.5, 25, 50, and 75% of its wild-type value to mimic loss-of-function mutations, and 125, 150, 175, and 200% of its wild-type value to mimic gain-of-function mutations.

![Dynamic clamp setup. Ultrarapid delayed rectifier K^+^ current (I~Kur~) and inward rectifier potassium current (I~K1~) were computed in real time on a PC running the Linux operating system and Real-Time Experiment Interface (RTXI) software ([@B43]), based on the acquired membrane potential (V~m~) of the human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM). Data were recorded on an Apple Macintosh computer using custom software to visualize and control the experiment. The sum of the stimulus current (I~stim~), I~K1~, and I~Kur~ resulted in the current that was injected into the hiPSC-CM (I~in~). Sample rates were 30 kHz (Δt~1~ = 33.33 μs) and 20 kHz (Δt~2~ = 50 μs).](fcell-08-00536-g002){#F2}

### I~Kur~ Equations {#S2.SS2.SSS5}

To compute I~Kur~ in our dynamic clamp system, I~Kur~ equations of the comprehensive human atrial myocyte model by [@B33] were used. These equations were also adopted by [@B24] in their human atrial action potential and Ca^2+^ model and read:
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In these equations, the dimensionless Hodgkin and Huxley-type activation and inactivation gating variables, ranging between 0 and 1, are denoted by a~ur~ and i~ur~, respectively, whereas I~Kur~ (in pA/pF), g~Kur~ (in nS/pF), V (in mV), E~K~ (in mV), and t (in s) denote the ultrarapid delayed rectifier outward K^+^ current, its fully activated conductance, the membrane potential, the K^+^ reversal potential, and the time, respectively. The steady-state values of a~ur~ and i~ur~ are denoted by a~ur,∞~ and i~ur,∞~, respectively, and the associated time constants by τ~aur~ (in s) and τ~iur~ (in s), respectively. As in the models by [@B33] and [@B24], a default value of 0.045 nS/pF was used for g~Kur~. Of note, [@B33] based this value on experimental data on I~Kur~ density in human atrial myocytes.

Statistical Analysis {#S2.SS3}
--------------------

Data are presented as mean ± SEM. Statistical analysis was carried out with SigmaStat 3.5 software (Systat Software, Inc., San Jose, CA, United States). Native I~Kur~ density of atrial- and ventricular-like hiPSC-CMs was compared with an independent samples *t*-test. Two-way repeated measures ANOVA followed by the Student--Newman--Keuls *post hoc* test was used for comparing AP parameters of atrial- and ventricular-like hiPSC-CMs in absence or presence of 4-AP. One-way repeated measures ANOVA followed by the Student--Newman--Keuls *post hoc* test was used for comparing the effect of injecting virtual I~Kur~ at various densities into atrial- and ventricular-like hiPSC-CMs. *P* \< 0.05 was considered statistically significant.

Results {#S3}
=======

Atrial- and Ventricular-Like hiPSC-CM APs {#S3.SS1}
-----------------------------------------

APs were recorded from single atrial- and ventricular-like hiPSC-CMs that showed spontaneous beating upon visual inspection, clearly indicating a healthy and myocardial status. APs were elicited at 1 Hz and virtual I~K1~ was injected into the cells, based on the approach of [@B36], to stabilize the RMP and set it at a regular hyperpolarized value. [Figure 3B](#F3){ref-type="fig"} shows typical atrial- and ventricular-like hiPSC-CM APs. AP parameters, as illustrated in [Figure 3A](#F3){ref-type="fig"}, are summarized in [Table 1](#T1){ref-type="table"}. Atrial-like hiPSC-CMs repolarize faster than ventricular-like APs, resulting in a significantly shorter APD~20~, APD~50~, and APD~90~. The ventricular-like APs have a prominent plateau phase at relatively positive potentials, in contrast with the atrial-like hiPSC-CMs that show a less prominent plateau phase at less positive potentials, if any plateau at all. Consequently, APPlatA was significantly smaller in atrial-like hiPSC-CMs and thus appeared a strong tool to distinguish between atrial-like and ventricular-like hiPSC-CMs. APA and dV/dt~max~ did not differ between the atrial- and ventricular-like hiPSC-CMs, but RMP was less negative in ventricular-like hiPSC-CMs.

![Control atrial- and ventricular-like hiPSC-CM APs. **(A)** AP parameters used for analysis: resting membrane potential (RMP), maximum upstroke velocity (dV/dt~max~), AP amplitude (APA), AP duration at 20, 50, and 90% repolarization (APD~20~, APD~50~, and APD~90~, respectively), and AP plateau amplitude at 50 ms after reaching dV/dt~max~ (APPlatA). **(B)** Superimposed typical APs of an atrial-like hiPSC-CM (red line) and a ventricular-like hiPSC-CM (blue line). **(C)** Superimposed APs (top panel) and associated net current consisting of stimulus current and virtual I~K1~ injected through dynamic clamp (bottom panel) of an atrial-like hiPSC-CM in absence (red line) and presence of 50 μM 4-aminopyridine (4-AP) (black line). **(D)** Superimposed APs (top panel) and associated net injected current (bottom panel) of a ventricular-like hiPSC-CM. APs elicited at 1 Hz by a 3-ms stimulus of 100 pA. Note difference in time scale between panels **(C,D)**.](fcell-08-00536-g003){#F3}

###### 

AP parameters of atrial- and ventricular-like hiPSC-CMs in absence and presence of 4-AP.

                     Atrial-like hiPSC-CMs (*n* = 11)   Ventricular-like hiPSC-CMs (*n* = 10)                      
  ------------------ ---------------------------------- --------------------------------------- ------------------ ---------------------
  RMP (mV)           −81.31 ± 0.43                      −80.83 ± 0.65                           −75.52 ± 1.69\*    −74.92 ± 1.71^\#^
  dV/dt~max~ (V/s)   74.54 ± 13.10                      76.47 ± 13.41                           83.70 ± 20.21      94.33 ± 24.43
  APA (mV)           96.61 ± 2.66                       98.33 ± 1.44                            105.61 ± 3.69      104.59 ± 3.88
  APD~20~ (ms)       35.86 ± 4.35                       38.13 ± 4.69                            77.73 ± 11.59\*    68.68 ± 10.67^‡\#^
  APD~50~ (ms)       60.99 ± 5.55                       65.05 ± 5.38                            127.93 ± 19.67\*   119.41 ± 18.09^‡\#^
  APD~90~ (ms)       81.27 ± 6.37                       86.76 ± 5.92^†^                         155.01 ± 21.49\*   147.68 ± 20.38^‡\#^
  APPlatA (mV)       53.61 ± 5.25                       60.53 ± 4.53^†^                         89.61 ± 4.51\*     89.42 ± 4.30^\#^

Data are AP parameters (mean ± SEM) of APs elicited at 1 Hz in absence (baseline) and presence of 50 μM 4-aminopyridine (4-AP). \*
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Next, the cells were superfused with 50 μM 4-AP to block intrinsic I~Kur~. [Figures 3C,D](#F3){ref-type="fig"}, top panels, show typical atrial- and ventricular-like hiPSC-CMs in absence (red and blue lines, respectively) and presence of 4-AP (black lines). The associated injected currents, which each consist of I~K1~ and the 3-ms stimulus current applied at 10 ms, are displayed in the bottom panels of [Figures 3C,D](#F3){ref-type="fig"}. In atrial-like hiPSC-CMs, I~Kur~ blockade resulted in a significantly increased APD~90~ and APPlatA, while other AP parameters were unaffected ([Table 1](#T1){ref-type="table"}). In contrast, in ventricular-like hiPSC-CMs, APD~20~, APD~50~ and APD~90~ were significantly decreased upon I~Kur~ blockade ([Table 1](#T1){ref-type="table"}). The small AP shortening likely results from a time effect rather than a drug effect because I~Kur~ is virtually absent in our ventricular-like hiPSC-CMs. Comparing atrial- with ventricular-like APs during I~Kur~ blockade, most AP parameters still differ significantly, except APA and dV/dt~max~.

Native I~Kur~ {#S3.SS2}
-------------

Native I~Kur~ density in atrial- and ventricular-like hiPSC-CMs was quantified during 200-ms depolarizing voltage clamp steps as the current sensitive to 50 μM 4-AP. [Figure 4A](#F4){ref-type="fig"} shows typical examples in an atrial-like (red trace) and a ventricular-like hiPSC-CM (blue trace). On average, I~Kur~ density in atrial-like hiPSC-CMs was significantly larger than in ventricular-like hiPSC-CMs, with densities of 1.88 ± 0.49 (*n* = 17) and 0.26 ± 0.26 (*n* = 17) pA/pF, respectively ([Figure 4B](#F4){ref-type="fig"}).

![Density of I~Kur~ measured as 50 μM 4-AP-sensitive current. **(A)** Typical 4-AP-sensitive currents in an atrial- and a ventricular-like hiPSC-CM (red and blue traces, respectively) upon 200-ms depolarizing voltage clamp steps to +50 mV from a holding potential of −50 mV. **(B)** I~Kur~ density in 17 atrial- and 17 ventricular-like hiPSC-CMs. \**P* \< 0.05.](fcell-08-00536-g004){#F4}

If the voltage clamp protocol of [Figure 4A](#F4){ref-type="fig"} is repeated in computer simulations with the [@B33] human atrial myocyte model ([@B53]), an I~Kur~ density of 5.45 pA/pF is obtained. We regard the latter as a realistic value for human atrial myocytes since [@B33] based the characteristics of their model I~Kur~ on experimental data on I~Kur~ from isolated human atrial myocytes.

Effects of Baseline Virtual I~Kur~ on APs of Atrial- and Ventricular-Like hiPSC-CMs {#S3.SS3}
-----------------------------------------------------------------------------------

Next, we studied the effects of a virtual I~Kur~ on APs of atrial and ventricular-like hiPSC-CMs using dynamic clamp. In the human heart, I~Kur~ is highly atrial-specific ([@B17]; [@B23]). However, the dynamic clamp technique allowed us to inject a virtual I~Kur~ in both atrial- and ventricular-like hiPSC-CMs and thus assess to which extent this made their action potential morphology become similar. In either case, 4-AP (50 μM) was present to ensure that any native I~Kur~ was blocked ([@B49]) and from here on we name this condition 0% I~Kur~. First, we injected a virtual I~Kur~ as implemented in the [@B33] human atrial myocyte model, i.e., with the aforementioned 5.45 pA/pF density at +50 mV, which we here consider as 100% density.

[Figures 5A,B](#F5){ref-type="fig"}, top panels, show typical examples of APs recorded from atrial- and ventricular-like hiPSC-CM at 0% (red and blue lines, respectively) and 100% I~Kur~ (black lines). The injected current, which now consists of I~K1~, 0% or 100% I~Kur~, and a short stimulus current, is shown in the middle panels of [Figures 5A,B](#F5){ref-type="fig"}. The average effects on the AP parameters of 11 atrial- and 10 ventricular-like hiPSC-CMs appear as the bars at 0% and 100% I~Kur~ in [Figures 6A--H](#F6){ref-type="fig"}, [7A--F](#F7){ref-type="fig"}, in which each of the AP parameters is expressed as a percentage of its value obtained at 100% I~Kur~. Injection of I~Kur~ shortened the AP of both atrial- and ventricular-like hiPSC-CMs, while the AP plateau was suppressed ([Figures 5](#F5){ref-type="fig"}, [6](#F6){ref-type="fig"}). dV/dt~max~ was unaltered in both atrial-and ventricular-like hiPSC-CMs, but in atrial-like hiPSC-CMs RMP was significantly more negative and APA significantly larger in absence than in presence of I~Kur~ ([Figure 7](#F7){ref-type="fig"}). The small 1.2% difference in RMP, equivalent to a 1.0-mV hyperpolarization, is likely a false positive because injection of various amounts of I~Kur~ did not affect the RMP in either atrial-like or ventricular-like hiPSC-CMs (see below).

![Effect of injection of 100% virtual I~Kur~ through dynamic clamp on APs of atrial- and ventricular-like hiPSC-CMs. **(A)** Superimposed APs (top panel) of an atrial-like hiPSC-CM at 0% (red line) and 100% virtual I~Kur~ (black line) and associated net injected current (middle panel), consisting of I~K1~, 0% or 100% I~Kur~, and a short stimulus current, as shown in the bottom panel in case of 100% I~Kur~. **(B)** Superimposed APs (top panel), associated net injected current (middle panel), and its individual components in case of 100% I~Kur~ (bottom panel) of a ventricular-like hiPSC-CM. **(C,D)** Phase plane plots (top panel) of the action potentials and injected currents of panels **(A,B)** with their individual components in case of 100% I~Kur~ (bottom panel). APs elicited at 1 Hz by a 3-ms stimulus of 100 pA. Note difference in time scale between panels **(A,B)**.](fcell-08-00536-g005){#F5}

![**(A,B)** APD~20~, **(C,D)** APD~50~, **(E,F)** APD~90~, and **(G,H)** APPlatA of atrial- and ventricular-like hiPSC-CMs (left and right panels, respectively) at virtual I~Kur~ densities ranging from 0 to 200%. AP parameters are expressed as percentage relative to their value at 100% I~Kur~ density (bleached bars). Data from 11 atrial- and 10 ventricular-like hiPSC-CMs. \**P* \< 0.05.](fcell-08-00536-g006){#F6}

![**(A,B)** RMP, **(C,D)** dV/dt~max~, and **(E,F)** APA of atrial- and ventricular-like hiPSC-CMs (left and right panels, respectively) at virtual I~Kur~ densities ranging from 0 to 200%. AP parameters are expressed as percentage relative to their value at 100% I~Kur~ density (bleached bars). Data from 11 atrial- and 10 ventricular-like hiPSC-CMs. \**P* \< 0.05.](fcell-08-00536-g007){#F7}

The phase plane plots of [Figures 5C,D](#F5){ref-type="fig"} show the injected currents of the middle panels of [Figures 5A,B](#F5){ref-type="fig"} plotted against the associated membrane potentials of the APs shown in the top panels of [Figures 5A,B](#F5){ref-type="fig"}. The start and the end of the negative depolarizing current that flows during the stimulus are indicated by downward and upward vertical arrows, respectively. The black loops of the phase plane plots clearly show that I~Kur~ is a repolarizing current that is already activated during the 3-ms stimulus and stays active until repolarization reaches −40 to −50 mV and the black traces 'fuse' with the red and blue traces of the action potentials without I~Kur~ (horizontal arrows). At these negative potentials, I~Kur~ becomes small because of both deactivation---rather than inactivation, which is much slower---and diminishing driving forces. The maximum I~Kur~ during the atrial-like AP is slightly larger compared to the ventricular-like AP because in this particular example the atrial-like AP reaches a higher peak than the ventricular-like AP, which results in a larger driving force for I~Kur~.

Effects of I~Kur~ Loss-of-Function Mutations in Atrial- and Ventricular-Like hiPSC-CMs {#S3.SS4}
--------------------------------------------------------------------------------------

Next, we studied the effects of loss-of-function mutations in *KCNA5*, resulting in a decrease in I~Kur~. Therefore, we decreased the fully activated conductance of the virtual I~Kur~ conductance to 75, 50, 25, and 12.5% of its control value. [Figure 8](#F8){ref-type="fig"} shows typical examples of the effects on the APs of atrial- and ventricular-like hiPSC-CMs. The average changes in AP parameters are shown in [Figures 6](#F6){ref-type="fig"}, [7](#F7){ref-type="fig"}. In both atrial- and ventricular-like hiPSC-CMs, APD~20~, APD~50~, and APD~90~ significantly increased upon a reduction in I~Kur~ ([Figures 6A--F](#F6){ref-type="fig"}). However, while the increase in APD~90~ in atrial-like APs is only present upon severe I~Kur~ reduction, APD~90~ prolongation in ventricular-like APs is already present at a mild reduction ([Figures 6E,F](#F6){ref-type="fig"}). APPlatA was significantly increased in both atrial- and ventricular-like APs ([Figures 6G,H](#F6){ref-type="fig"}). RMP and dV/dt~max~ were unaffected ([Figures 7A--D](#F7){ref-type="fig"}), whereas a slight increase in APA was observed, but only in atrial-like hiPSC-CMs at severe reductions of I~Kur~ ([Figures 7E,F](#F7){ref-type="fig"}).

![Effect of I~Kur~ loss-of-function mutations on APs of atrial- and ventricular-like hiPSC-CMs. **(A)** Superimposed APs of an atrial-like hiPSC-CM upon injection of 12.5--100% virtual I~Kur~ through dynamic clamp and associated injected current (bottom panel), consisting of I~K1~, 12.5--100% I~Kur~, and a short stimulus current. **(B)** Superimposed APs (top panel) and associated injected current (bottom panel) of a ventricular-like hiPSC-CM. APs elicited at 1 Hz by a 3-ms stimulus of 100 pA. Note difference in time scale between panels **(A,B)**.](fcell-08-00536-g008){#F8}

Effects of I~Kur~ Gain-of-Function Mutations in Atrial- and Ventricular-Like hiPSC-CMs {#S3.SS5}
--------------------------------------------------------------------------------------

Finally, we studied the effects of gain-of-function mutations in *KCNA5*, resulting in an increase in I~Kur~. Therefore, we increased the fully activated conductance of the virtual I~Kur~ conductance to 125, 150, 175, and 200% of its control value. [Figure 9](#F9){ref-type="fig"} shows typical examples of the effects on the APs of atrial- and ventricular-like hiPSC-CMs. The average changes in AP parameters are shown in [Figures 6](#F6){ref-type="fig"}, [7](#F7){ref-type="fig"}. In both atrial- and ventricular-like hiPSC-CMs, APD~20~ and APD~50~ significantly shortened, but only when I~Kur~ was strongly increased ([Figures 6A--D](#F6){ref-type="fig"}). APD~90~ was significantly reduced in ventricular-like, but not in atrial-like hiPSC-CMs ([Figures 6E,F](#F6){ref-type="fig"}). APPlatA only showed a significant decrease in ventricular-like hiPSC-CMs ([Figures 6G,H](#F6){ref-type="fig"}). Other AP parameters were unaffected upon increases in I~Kur~ ([Figure 7](#F7){ref-type="fig"}).

![Effect of I~Kur~ gain-of-function mutations on APs of atrial- and ventricular-like hiPSC-CMs. **(A)** Superimposed APs of an atrial-like hiPSC-CM upon injection of 100--200% virtual I~Kur~ through dynamic clamp and associated injected current (bottom panel), consisting of I~K1~, 100--200% I~Kur~, and a short stimulus current. **(B)** Superimposed APs (top panel) and associated injected current (bottom panel) of a ventricular-like hiPSC-CM. APs elicited at 1 Hz by a 3-ms stimulus of 100 pA. Note difference in time scale between panels **(A,B)**.](fcell-08-00536-g009){#F9}

Discussion {#S4}
==========

Overall, the APs of our atrial-like hiPSC-CMs were substantially shorter and had a lower AP plateau than those of our ventricular-like hiPSC-CMs, in qualitative agreement with previous studies on atrial- and ventricular-like hiPSC-CMs ([@B34]; [@B48]; [@B3]; [@B10]; [@B31]; [@B47]). There are some quantitative differences in AP parameters with previous studies, but these are likely due to differences in cell lines, differences in differentiation protocols, absence or presence of I~K1~ injection, and a different definition of AP plateau amplitude. The differences in AP parameters of our atrial- and ventricular-like hiPSC-CMs would have been even larger if we had supplied our atrial-like hiPSC-CMs with a more atrial-specific I~K1~, as not only observed in human heart ([@B50]), but also in canine, murine and sheep heart ([@B16]; [@B42]; [@B8]). Of note, [@B18] recently published a detailed *in silico* study of the effects of several I~K1~ formulations on AP duration of hiPSC-CMs.

Maximum sustained native I~Kur~ density was larger in our atrial-like hiPSC-CMs than in our ventricular-like hiPSC-CMs. Yet, with a value of 1.88 ± 0.49 pA/pF at +50 mV, the I~Kur~ density of our atrial-like hiPSC-CMs was small in comparison with that of freshly isolated human atrial myocytes, for which [@B2] observed a density of 5.1 ± 0.3 pA/pF for peak I~Kur~ and 4.7 ± 0.2 pA/pF for late I~Kur~ during a 300-ms voltage clamp step to +40 mV at 22°C (114 cells, 32 hearts). Therefore, we decided to block native I~Kur~ and use dynamic clamp to study the effects of I~Kur~, using a virtual I~Kur~ with characteristics, including its density, based on observations made in freshly isolated human atrial myocytes.

Due to the relatively low native I~Kur~ density of our atrial- and ventricular-like hiPSC-CMs, it was not surprising that blockade of I~Kur~ by 4-AP had only minor effects on AP parameters. When native I~Kur~ was replaced with virtual I~Kur~ with 100% density, similar to I~Kur~ density in freshly isolated human atrial myocytes, more pronounced effects on AP parameters were observed. In atrial-like hiPSC-CMs, APD~20~ shortened substantially, whereas APD~50~ shortened only moderately and APD~90~ even less so. In ventricular-like hiPSC-CMs, on the other hand, not only APD~20~, but also APD~50~ and APD~90~ shortened substantially upon injection of virtual I~Kur~. The more pronounced effect on APD in ventricular-like hiPSC-CMs is likely related to the longer and more positive AP plateau potentials leading to more functional consequences of I~Kur~. The observed decrease in APD~20~ was accompanied by a lowering of the AP plateau in both atrial- and ventricular-like hiPSC-CMs.

We only performed experiments at a pacing rate of 1 Hz and not at higher pacing rates. Therefore, we were unable to confirm that the relative contribution of I~Kur~ to AP repolarization increases with increasing pacing rate ([@B22]; [@B1]). [@B1] carried out comprehensive computer simulations with the [@B9] human atrial myocyte model, in which the I~Kur~ formulation was updated in accordance with the experimental observations on I~Kur~ inactivation by [@B21]. They found that I~Kur~ did not inactivate significantly at high pacing rates and, consequently, the contribution of I~Kur~ to repolarization was mainly determined by its (fast) activation kinetics. Accordingly, rate-dependent changes in I~Kur~ were largely determined by changes in action potential morphology. In computer simulations with the [@B33] model, on which we based our I~Kur~ formulation, we made similar observations (data not shown). We aim to test the rate dependence of the effects of I~Kur~ on AP repolarization in future experiments on hiPSC-CMs.

In both atrial- and ventricular-like hiPSC-CMs, simulation of loss-of-function mutations through lowering of the virtual I~Kur~ density from 100% to 12.5--75% of its control value, resulted in prolongation of the AP and raise of its plateau, in line with the differences in AP parameters that were observed between 0 and 100% I~Kur~. [@B34] found that knock-out of *KCNA5* in hiPSC-CMs, representing a complete loss-of-function, may result in the development of EADs, which, however, were not observed in the present study, likely due to our higher pacing frequency. At I~Kur~ densities \> 100%, simulating gain-of-function mutations, effects on AP parameters were somewhat less pronounced. In both atrial- and ventricular-like hiPSC-CMs, APD~20~ was only significantly decreased upon an increase in I~Kur~ density to 200%. A significant lowering of the AP plateau, together with AP shortening, was only observed in ventricular-like hiPSC-CMs.

Although the sustained native I~Kur~ density at +50 mV was small in our atrial-like hiPSC-CMs (1.88 ± 0.49 pA/pF, *n* = 17), it was still significantly larger than in our ventricular-like hiPSC-CMs (0.26 ± 0.26 pA/pF, *n* = 17). Within our atrial-like hiPSC-CM population we noted cells lacking I~Kur~ ([Figure 4B](#F4){ref-type="fig"}), although atrial-like hiPSC-CM generation using retinoic acid has been shown to generate 90--95% atrial-like hiPSC-CMs ([@B10]), with the rest being sinus- or ventricular-like hiPSC-CMs. Since hiPSC-CMs display an immature phenotype, it is possible that not all atrial-like hiPSC-CMs have developed I~Kur~ densities large enough to be detected as 4-AP sensitive current in a voltage clamp setting. Our recorded I~Kur~ densities are lower than those of the only other known quantification of I~Kur~ density in atrial- and ventricular-like hiPSC-CMs ([@B30]). In the study by [@B30], which has only been published in abstract form, the sustained I~Kur~ density at +50 mV amounted to 3.71 ± 0.55 pA/pF (*n* = 5) in atrial-like hiPSC-CMs, which was significantly larger than that of ventricular-like hiPSC-CMs (1.00 ± 0.10 pA/pF, *n* = 16). To distinguish between the two types of hiPSC-CMs based on I~Kur~ densities would require further investigation, although the available data suggest a trend of a significantly larger I~Kur~ density in atrial-like hiPSC-CMs.

Of note, all AP parameters of our atrial- and ventricular-like hiPSC-CMs except dV/dt~max~ and APA were not only different under control conditions, but also upon blockade of I~Kur~ by 4-AP, indicating that the two types of hiPSC-CMs are not only different in their level of K~v~1.5 expression, as determined by I~Kur~ density, and suggesting that differences in membrane currents other than I~Kur~ also contribute to the observed differences in AP parameters. This result is in line with previous findings by both [@B34] and [@B31], who found that knock-out of *KCNA5* or I~Kur~ blockade by 4-AP in atrial-like hiPSC-CMs did not result in completely ventricular-like APs. These findings are, however, to some extent at odds with those by [@B30], who noticed that the APs of their atrial-like hiPSC-CMs took on a ventricular-like shape when treated with 4-AP, which strongly suggested that I~Kur~ is the major determinant of atrial action potential morphology. Conversely, they observed that injection of a virtual I~Kur~ in ventricular-like hiPSC-CMs, employing the dynamic clamp technique using oocytes expressing a cloned K~v~1.5 current, resulted in APs similar to those of atrial-like hiPSC-CMs. Apart from the studies by [@B30], [@B34], and [@B31], data on I~Kur~ in hiPSC-CMs are limited and the electrophysiology of I~Kur~ in atrial- and ventricular-like hiPSC-CMs remains largely unknown.

Apart from demonstrating a link between altered I~Kur~ density and changes in AP parameters, I~Kur~ has now been quantified in both atrial- and ventricular-like hiPSC-CMs. Thus, the present study provides additional data toward a complete characterization of individual membrane currents in hiPSC-CMs. Moreover, our study illustrates the potentials of dynamic clamp experiments on hiPSC-CMs, allowing manipulation of characteristics of the injected current in real time, thus facilitating direct, systematic, and efficient testing of changes in those characteristics. In the context of studying drug effects, including effects of anti-AF drugs, dynamic clamp may prove useful in the identification of potential drug targets and in testing model-based hypotheses ([@B41]). For instance, dynamic clamp experiments on atrial-like hiPSC-CMs with I~Kur~ based on specific loss- or gain-of-function mutations in *KCNA5* can be utilized to assess the cellular effects of these mutations as well as effects of dedicated pharmacological treatment through modulation of I~Kur~. Ultimately, this may lead to mutation-specific treatment of AF.
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